Elutia Inc. (ELUT) stock
ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/307% below fair value
$0.83−0.02 (-2.80%)
Close on Nov 18, 2026Market cap $36.76MP/E –Yield –
Elutia revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Elutia's revenue for the twelve months ending Jun 30, 2026 was $12.14M, down 0.3% year over year. For fiscal 2025 it was $12.29M, down 15.0% from the year before. The highest annual figure on record is $47.39M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.29M | -15.0% |
| FY2024 | Dec 31, 2024 | $14.47M | -41.5% |
| FY2023 | Dec 31, 2023 | $24.75M | +3.8% |
| FY2022 | Dec 31, 2022 | $23.85M | -49.7% |
| FY2021 | Dec 31, 2021 | $47.39M | +11.0% |
| FY2020 | Dec 31, 2020 | $42.68M | -0.5% |
| FY2019 | Dec 31, 2019 | $42.90M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.43M | -11.6% |
| Q1 FY2026 | Mar 31, 2026 | $3.11M | +5.5% |
| Q4 FY2025 | Dec 31, 2025 | $3.27M | +16.2% |
| Q3 FY2025 | Sep 30, 2025 | $3.32M | -9.3% |
| Q2 FY2025 | Jun 30, 2025 | $2.75M | -56.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.95M | -55.9% |
| Q4 FY2024 | Dec 31, 2024 | $2.82M | -52.1% |
| Q3 FY2024 | Sep 30, 2024 | $3.66M | -40.2% |
| Q2 FY2024 | Jun 30, 2024 | $6.29M | -0.9% |
| Q1 FY2024 | Mar 31, 2024 | $6.69M | +4.7% |
| Q4 FY2023 | Dec 31, 2023 | $5.88M | -53.5% |
| Q3 FY2023 | Sep 30, 2023 | $6.13M | -46.7% |
| Q2 FY2023 | Jun 30, 2023 | $6.35M | -41.5% |
| Q1 FY2023 | Mar 31, 2023 | $6.39M | -44.3% |
| Q2 FY2022 | Jun 30, 2022 | $12.64M | +3.9% |
| Q1 FY2022 | Mar 31, 2022 | $11.50M | -10.8% |
| Q4 FY2021 | Dec 31, 2021 | $10.86M | -12.9% |
| Q3 FY2021 | Sep 30, 2021 | $11.49M | -2.5% |
| Q2 FY2021 | Jun 30, 2021 | $12.16M | +41.7% |
| Q1 FY2021 | Mar 31, 2021 | $12.88M | +30.6% |
| Q4 FY2020 | Dec 31, 2020 | $12.47M | +3.4% |
| Q3 FY2020 | Sep 30, 2020 | $11.77M | +5.7% |
| Q2 FY2020 | Jun 30, 2020 | $8.58M | – |
| Q1 FY2020 | Mar 31, 2020 | $9.86M | – |
| Q4 FY2019 | Dec 31, 2019 | $12.05M | – |
| Q3 FY2019 | Sep 30, 2019 | $11.14M | – |
See a number that looks wrong?